Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.06% $9.10
America/New_York / 23 jun 2023 @ 15:58
FUNDAMENTALS | |
---|---|
MarketCap: | 1 199.45 mill |
EPS: | -0.540 |
P/E: | -16.84 |
Earnings Date: | Aug 07, 2023 |
SharesOutstanding: | 131.88 mill |
Avg Daily Volume: | 5.66 mill |
RATING 2023-06-23 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -16.84 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.87x |
Company: PE -16.84 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 8.91 - 9.27 ( +/- 2.01%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-26 | Bvf Partners L P/il | Sell | 43 139 | Common Stock, par value $0.001 |
2023-06-26 | Bvf Partners L P/il | Sell | 12 | Series X Convertible Preferred Stock |
2023-06-26 | Bvf Partners L P/il | Sell | 17 | Series X1 Convertible Preferred Stock |
2023-06-26 | Bvf Partners L P/il | Sell | 120 000 | Stock Option (Right to Buy) |
2023-06-26 | Bvf Partners L P/il | Sell | 60 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-81.30 |
Last 99 transactions |
Buy: 2 253 317 | Sell: 15 023 868 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $9.10 (0.06% ) |
Volume | 5.56 mill |
Avg. Vol. | 5.66 mill |
% of Avg. Vol | 98.18 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.